Nita Maihle, PhD

• Professor of Obstetrics, Gynecology, and Reproductive Sciences, of Pathology and of Pharmacology
• Director, Biology of Reproductive Tract Cancers Program

Biography

Ongoing studies include fundamental aspects of receptor/extracellular matrix regulation by sEGFR/sHER’s, with an emphasis on cell survival signaling, as well as the clinical development of these newly discovered HER receptor isoforms as biotherapeutics, and also as prognostic, diagnostic, and theragnostic biomarkers (serum/tissue/tumor). More recent studies include the discovery of mechanisms underlying primary resistance to biologically-targeted HER-directed therapeutics.

Selected Publications

Rodland, K. and N. J. Maihle, 2011. Searching for a system: The Quest for Ovarian Cancer Biomarkers. Cancer Biomarkers. 8 (4-5): 223-230. PMID: 22045355

*Wilken, J. A., Baron, A. T., Foty, R. A., McCormick, D. J., and N. J. Maihle, 2011. Identification of immunoreactive regions of homology between soluble Epidermal Growth Factor Receptor (sEGFR) and alpha5-integrin. Biochemistry. 50(20):4309-21. PMID: 21491912

*Wilken, J. A., Baron, A. T., and N. J. Maihle, 2011. 'The EGFR Conundrum: EGFR-based Diagnostics in the Era of Personalized Medicine. Proc. 9th International AACR Conference on Prevention in Cancer Research, In Press.

*Wilken, J. A., Baron, A. T., and N. J. Maihle, 2011. The Epidermal Growth Factor Receptor Conundrum. Cancer. 117(11):2358-2360. PMID: 21157953

*Wilken, J.A. and N.J. Maihle (2010) Primary resistance to trastuzumab: New tricks for an old drug. Ann. New York Acad. Sci., 1210:53-65.

*Wilken, J.A., *Webster, K.T., N.J. Maihle. 2010. Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics. J. Ovarian Res. Mar 27;3:7. PMID: 20346177

Peng, S., Maihle, N. J., and Y. Huang. 2010. Pluripotency factors Lin28 and Oct4 identify a subpopulation of stem cell-like cells in ovarian cancer. Oncogene 9(14):2153-9. PMID: 20101213

*Albitar, L., Pickett, G., Morgan, M., *Wilken, J., Maihle, N.J., and K. Leslie. 2010. EGFR isoforms and gene regulation in human endometrial cancer cells. Mol. Cancer. 9(1):166. PMID: 20579378

Baron, A.T., *Wilken, J.A., Haggstrom, D.E., Goodrich, S.T., and N.J. Maihle. (2009) Clinical implementation of soluble epidermal growth factor receptor (sEGFR) as a theragnostic serum biomarker of breast, lung, and ovarian cancer. Investigational Drugs Journal 12(5):302-8. PMID: 19431095

Narayan M., *Wilken J.A., Baron, A.T., Kimbler, K.D., Harris L.N., Maihle N.J., (2009) "Trastuzumab-induced HER reprogramming in 'resistant' breast cancer cells" Cancer Res. 69(6):2191-2194. PMID: 1868732 §Selected as a ‘Priority Report’ in the March, 2009 volume of Cancer Research

Baron A.T, ,*Lafky J.M, ,*Boardman C.H., Cora E.M., Buenafe M.C., Liu D., Rademaker A., Fishman D.A., Podratz K.C., ,*Reiter J.L., N.J. Maihle. 2009. Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer. Cancer Treat Res. 2009;149:189-202. PMID 19763437

*Perez-Torres, M., Valle, B.L., Maihle, N.J., Negrón-Vega, L., Nieves-Alicea, R., and E.M. Cora. (2008) Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp Cell Res. 314(16): 2907-18. PMID: 18687326

Lafky, J. M., *Wilken, J.A., Baron, A. T., and Maihle, N. J. (2008). Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim. Biophy. Acta (Cancer Reviews), 1785: 232-265. PMID: 18291115

*Lafky, J. M., *Baron, A. T., Cora, E. M., Hillman, D. W, Suman, V. J., Perez, E. A., Ingle, J. N., and N.J. Maihle (2005) Serum sEGFR concentrations decrease in postmenopausal metastatic breast carcinoma patients treated with letrozole. Cancer Research 65(8):3059-3062. PMID: 158833834 §Selected as a ‘Priority Report’ in the April, 2005 volume of Cancer Research.